CytoDyn has engaged Syneos Health as the contract research organization for its upcoming Phase II study exploring leronlimab and its effects on chronic inflammation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYDY:
- CytoDyn completes FDA meeting on Phase II Study of leronlimab
- CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
- CytoDyn Resolves Lawsuit, Secures Payments, and Clears Debt
- CytoDyn announces settlement with Amarex Clinical Research
- CytoDyn Announces Settlement with Amarex Clinical Research LLC
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue